8956 Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Eligibility Error 

Rate Measurement in Medicaid and the 

Children’s Health Insurance Program; 

Use: The collection of information is 

necessary for CMS to produce national 

error rates for Medicaid and CHIP as 

required by Public Law 107–300, the 

IPIA of 2002. The collection of 

information is also necessary to 

implement provisions from the 

Children’s Health Insurance Program 

Reauthorization Act of 2009 (CHIPRA) 

(Pub. L. 111–3) with regard to the 

Medicaid Eligibility Quality Control 

(MEQC) and Payment Error Rate 

Measurement (PERM) programs. The 

information collected from the States 

selected for review will be used by CMS 

to ensure States use a statistically sound 

sampling methodology, to ensure the 

States complete reviews on all cases 

sampled, and will be used by the federal 

contractor to calculate State and 

national Medicaid and CHIP eligibility 

error rates. Form Number: CMS–10184 

(OMB#: 0938–1012); Frequency: 

Reporting—Occasionally; Affected 

Public: State, Local, Tribal 

Governments; Number of Respondents: 

34; Total Annual Responses: 53; Total 

Annual Hours: 942,764. (For policy 

questions regarding this collection 

contact Jessica Woodard at 410–786– 

9249. For all other issues call 410–786– 

1326.) 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, access CMS Web site 

address at http://www.cms.hhs.gov/ 

PaperworkReductionActof1995, or 

E-mail your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov, or call the 

Reports Clearance Office on (410) 786– 

1326. 

To be assured consideration, 

comments and recommendations for the 

proposed information collections must 

be received by the OMB desk officer at 

the address below, no later than 5 p.m. 

on March 29, 2010: 

OMB, Office of Information and 

Regulatory Affairs, 

Attention: CMS Desk Officer, 

Fax Number: (202) 395–6974, 

E-mail: OIRA_submission@omb.eop.gov. 

Dated: February 22, 2010. 

Michelle Shortt, 

Director, Regulations Development Group, 

Office of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2010–4020 Filed 2–25–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–10–10BR] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Maryam I. Daneshvar, 

CDC Acting Reports Clearance Officer, 

1600 Clifton Road, MS–D74, Atlanta, 

GA 30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Evaluation and Development of 

Hearing Loss Interventions—New— 

National Institute for Occupational 

Safety and Health (NIOSH), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

NIOSH, under Public Law 91–596, 

Sections 20 and 22 (Section 20–22, 

Occupational Safety and Health Act of 

1970) has the responsibility to conduct 

research relating to innovative methods, 

techniques, and approaches dealing 

with occupational safety and health 

problems. 

This research relates to reducing the 

incidence of noise induced hearing loss 

in the coal mining industry through 

improved development and 

dissemination of hearing loss 

prevention products. The overall 

objective of this project is to improve 

the effectiveness of hearing loss 

prevention research products through 

development, refinement, promotion, 

and long term evaluation. Research 

products developed in previous projects 

and new products developed in current 

projects will be evaluated and promoted 

for industry-wide adoption and impact. 

Noise-induced hearing loss (NIHL) is 

the most common occupational illness 

in the United States today, with 30 

million workers exposed to excessive 

noise levels. Mining has the highest 

prevalence of hazardous noise exposure 

of any major industry sector (Tak, Davis, 

& Calvert, 2009) and is second only to 

the railroad industry in prevalence of 

workers reporting hearing difficulty 

(Tak & Calvert, 2008). The Hearing Loss 

Prevention Branch at NIOSH Office of 

Mine Safety and Health Research 

(OMSHR) has developed multiple 

hearing loss prevention research 

products with the intent of controlling 

noise exposure and reducing the 

occurrence of NIHL in mining. 

However, many of the products are not 

widely used in industry. The current 

project has several goals related to 

determining the effectiveness of our 

products and developing additional 

products; however it is also necessary to 

determine why the products are not 

receiving greater field utilization so that 

we can amend the procedure for 

dissemination and to assure that future 

products are transferred to industry in a 

more efficient manner. 

The outcomes of this project will 

include a culmination of various 

physical measures such as noise 

dosimetry, noise measures, and 

audiometry. These are common industry 

hygiene methods that typically do not 

require special approval. However, it 

will also be necessary to conduct semistructured interviews and 

questionnaire-based assessments with 

various mine personnel who are using 

NIOSH-developed noise controls to gain 

an understanding of the barriers to 

acceptance. Employees will be asked 

about their motivation to implement 

noise controls, their attitude towards the 

specific control being assessed, their 

attitude toward safety, and the methods 

they use to find and implement health 

and safety information. These 

interviews will take place with health 


sroberts on DSKD5P82C1PROD with NOTICES
Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 8957 

and safety managers, mine foremen, 

maintenance supervisors, production 

coordinators and operators of 

equipment with installed noise controls. 

The proposed time schedule for 

conducting these assessments is before 

installation of a control and on a 

predetermined schedule for the duration 

of the life of the control. For example, 

one noise control may have an expected 

performance life of 6 months. In that 

case the interviews will occur before 

installation, 2 weeks, 6 weeks, 14 

weeks, and 24 weeks post installation. 

Although we plan to follow this 

general time table, due to the nature of 

the mining industry, slight deviation 

may occur. No noise control will require 

greater than 5 interviews per 

respondent. The goal is to achieve 6 

mines and 6 individuals per mine per 

noise control. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Managers Foreman Supervisors Coordinators Operators.Assessment of the Urethane-Coated 

Chain for Continuous Mining Machines.

36 5 20/60 60 

Managers Foreman Supervisors Coordinators Operators.Assessment of the Roof Bolting Machine Noise Control Products.36 5 20/60 60 

Managers Foreman Supervisors Coordinators Operators.Assessment for the Enclosure for 

Vibrating Screen.

36 5 20/60 60 

Total ........................................... ........................................................... 108 ........................ ........................ 180 

Dated: February 22, 2010. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2010–3999 Filed 2–25–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0373] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Mental Models 

Study of Recruitment and Retention of 

Pregnant Women Into An Asthma 

Pregnancy Registry 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by March 29, 

2010. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–7285, or e-mailed to 

oira_submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–NEW and 

title Mental Models Study of 

Recruitment and Retention of Pregnant 

Women Into An Asthma Pregnancy 

Registry. Also include the FDA docket 

number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Elizabeth Berbakos, Office of 

Information Management, Food and 

Drug Administration, 1350 Piccard Dr., 

PI50–400B, Rockville, MD 20850, 301– 

796–3792, 

Elizabeth.Berbakos@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Mental Models Study of Recruitment 

and Retention of Pregnant Women Into 

An Asthma Pregnancy Registry—(OMB 

Control Number 0910)—NEW 

The authority for FDA to collect the 

information derives from the FDA 

Commissioner’s authority, as specified 

in section 903(d)(2) of the Federal Food, 

Drug, and Cosmetic Act (21 U.S.C. 

393(d)(2)). 

The proposed information collection 

will help FDA advance public health by 

identifying priorities, perceptions, and 

communication needs about how 

pregnant women and their health care 

providers make decisions about 

participation in a pregnancy registry. 

Understanding these priorities, 

perceptions, and communication needs 

will foster more effective approaches to 

recruitment of pregnant women into 

pregnancy registries and full retention 

of those women until the end of the 

registry study period. Ultimately, early 

enrollment and complete followup of 

women in pregnancy registries will 

strengthen the quality of safety data 

about use of needed medications during 

pregnancy. 

Before a medication is approved by 

FDA for sale in the United States, 

pregnant women are rarely included in 

experimental research studies of the 

medication because of concerns that the 

experimental treatment may harm the 

developing fetus and/or the pregnant 

woman. As a result, when a medication 

is approved for marketing in the United 

States, little systematically collected 

human data are available to define the 

chance of serious side effects in 

pregnant women and/or their 

developing fetuses from use of the 

medication during pregnancy. 

A pregnancy registry is a research 

study conducted after a medication has 

been approved, during which pregnant 

women being treated with the 

medication are observed to identify 

possible harms to the woman and/or to 

her developing fetus. Pregnant women 

voluntarily enroll in a pregnancy 

registry; data about the pregnancy, 

labor, delivery, and newborn are 

collected and analyzed to identify any 

serious adverse outcomes and consider 

whether use of the medication may be 

linked to any observed harm. The 

quality of pregnancy registry data is 

enhanced by enrollment of women early 

in their pregnancy and by complete 

followup of all enrolled pregnancies to 

the end of the registry study period. 

Ultimately, high quality human 


sroberts on DSKD5P82C1PROD with NOTICES